创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology ADCC Platform: Leading a New Chapter in Tumor Immunotherapy

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-09 15:41
  • Views:

(Summary description)In the current field of biomedical research, tumor immunotherapy is undoubtedly one of the most promising therapeutic means. Among them, antibody-dependent cytotoxicity (ADCC), as an important immune mechanism, plays a pivotal role in tumor treatment. The ADCC platform built by InnoModels Biotechnology is based on this mechanism and provides powerful in vitro experimental support for tumor immunotherapy research.

InnoModels Biotechnology ADCC Platform: Leading a New Chapter in Tumor Immunotherapy

(Summary description)In the current field of biomedical research, tumor immunotherapy is undoubtedly one of the most promising therapeutic means. Among them, antibody-dependent cytotoxicity (ADCC), as an important immune mechanism, plays a pivotal role in tumor treatment. The ADCC platform built by InnoModels Biotechnology is based on this mechanism and provides powerful in vitro experimental support for tumor immunotherapy research.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-09 15:41
  • Views:
Information

In the current field of biomedical research, tumor immunotherapy is undoubtedly one of the most promising therapeutic means. Among them, antibody-dependent cytotoxicity (ADCC), as an important immune mechanism, plays a pivotal role in tumor treatment. The ADCC platform built by InnoModels Biotechnology is based on this mechanism and provides powerful in vitro experimental support for tumor immunotherapy research.
1、ADCC mechanism and tumor immunotherapy
ADCC is an antibody-mediated immune cell killing mechanism. When antibodies bind to antigens on the surface of tumor cells, these antibodies can bind to Fc receptors on the surface of immune cells (e.g., natural killer cells, NK cells), thereby activating these immune cells and causing them to attack tumor cells. In this process, NK cells, as key players, are responsible for attacking those tumor cells labeled by antibodies.

 


2. Characteristics of InnoModels Biotechnology ADCC platform
(1) Diversity of target cell choices: InnoModels' ADCC platform provides a variety of target cell choices, including tumor cell lines, primary tumor cells and genetically engineered cell lines. These target cell choices not only meet a wide range of research and testing needs, but also more realistically simulate the biological environment, providing closer to real experimental conditions for tumor immunotherapy research.
2) Abundance of effector cell sources: The platform also demonstrates its flexibility in the selection of effector cells. In addition to commercially available PBMC (peripheral blood mononuclear cells), there are also clinical patient-derived PBMC and the NK92 cell line, which is specifically designed for NK cell research. These diverse sources of effector cells allow researchers to choose the most appropriate cell type for specific research needs.
3) High-precision detection and analysis tools: The platform uses high-precision technologies such as flow assay, which can accurately distinguish between effector cells and target cells, providing accurate data support for research. At the same time, through flow technology, it can also accurately calculate the proportion of apoptotic cells, so as to intuitively assess the effect of ADCC.
3、Significance of the ADCC platform of InnoModels Biotechnology
InnoModels' ADCC platform not only provides powerful in vitro experimental support for tumor immunotherapy research, but also promotes the research progress in this field. Through this platform, researchers can gain a deeper understanding of the role of ADCC mechanism in tumor immunotherapy and provide theoretical support and practical guidance for the development of more effective tumor immunotherapy methods.
In conclusion, with its diverse selection of target and effector cells and high-precision detection and analysis methods, the ADCC platform of InnoModels Biotechnology has opened up a new path for tumor immunotherapy research. With the deepening of the research, we have reason to believe that this platform will play an even more important role in tumor immunotherapy in the future.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司